These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 14674736)

  • 1. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States).
    Li L; Yu H; Schumacher F; Casey G; Witte JS
    Cancer Causes Control; 2003 Oct; 14(8):721-6. PubMed ID: 14674736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
    Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
    J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.
    Mikami K; Ozasa K; Nakao M; Miki T; Hayashi K; Watanabe Y; Mori M; Sakauchi F; Washio M; Kubo T; Suzuki K; Wakai K; Nakachi K; Tajima K; Ito Y; Inaba Y; Tamakoshi A;
    Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():57-61. PubMed ID: 20553083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
    Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
    Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.
    Wolk A; Mantzoros CS; Andersson SO; Bergström R; Signorello LB; Lagiou P; Adami HO; Trichopoulos D
    J Natl Cancer Inst; 1998 Jun; 90(12):911-5. PubMed ID: 9637140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
    Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E
    J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
    Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.
    Miles FL; Goodman PJ; Tangen C; Torkko KC; Schenk JM; Song X; Pollak M; Thompson IM; Neuhouser ML
    Nutrients; 2017 Apr; 9(4):. PubMed ID: 28417914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.
    Allen NE; Key TJ; Appleby PN; Travis RC; Roddam AW; Rinaldi S; Egevad L; Rohrmann S; Linseisen J; Pischon T; Boeing H; Johnsen NF; Tjønneland A; Grønbaek H; Overvad K; Kiemeney L; Bueno-de-Mesquita HB; Bingham S; Khaw KT; Tumino R; Berrino F; Mattiello A; Sacerdote C; Palli D; Quirós JR; Ardanaz E; Navarro C; Larrañaga N; Gonzalez C; Sanchez MJ; Trichopoulou A; Travezea C; Trichopoulos D; Jenab M; Ferrari P; Riboli E; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1121-7. PubMed ID: 17548673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Douglas JB; Silverman DT; Pollak MN; Tao Y; Soliman AS; Stolzenberg-Solomon RZ
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2298-306. PubMed ID: 20699371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
    Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
    Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer.
    Friedrichsen DM; Hawley S; Shu J; Humphrey M; Sabacan L; Iwasaki L; Etzioni R; Ostrander EA; Stanford JL
    Prostate; 2005 Sep; 65(1):44-51. PubMed ID: 15800934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom.
    Young NJ; Metcalfe C; Gunnell D; Rowlands MA; Lane JA; Gilbert R; Avery KN; Davis M; Neal DE; Hamdy FC; Donovan J; Martin RM; Holly JM
    Cancer Causes Control; 2012 Jun; 23(6):907-17. PubMed ID: 22527168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
    Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R
    J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.
    Kaaks R; Toniolo P; Akhmedkhanov A; Lukanova A; Biessy C; Dechaud H; Rinaldi S; Zeleniuch-Jacquotte A; Shore RE; Riboli E
    J Natl Cancer Inst; 2000 Oct; 92(19):1592-600. PubMed ID: 11018095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.
    Chokkalingam AP; McGlynn KA; Gao YT; Pollak M; Deng J; Sesterhenn IA; Mostofi FK; Fraumeni JF; Hsing AW
    Cancer Res; 2001 Jun; 61(11):4333-6. PubMed ID: 11389055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.